Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

Inclusion Criteria:

1. At least 18 years old and maximum of 85 years old.
2. Subjects with a diabetic foot ulcer that is either superficial, e.g. not involvingtendon, capsule, or bone; or wounds that penetrate into tendon, capsule, bone and/orjoint.
3. Subjects, with the presence of Diabetes, must have a Glycosylated hemoglobin (HbA1c) ≤ 12% within 4 weeks prior to randomization
4. Index ulcer (i.e. current episode of ulceration) has been present for greater than 4weeks prior to the initial screening visit with no upper limit in duration ofnon-healing.
5. Subject has adequate circulation to the foot as documented by either: Skin perfusionpressure (SPP) measurement of ≥ 45 mmHg, Toe-brachial index (TBI) ≥ 0.6/ Toe pressuregreater than 40, Ankle-brachial index (ABI) between 0.60 and ≤ 1.3
6. Index ulcer is a minimum of 0.5 cm2 and a maximum of 25cm2 at randomization, prior tofirst study treatment.
7. The index ulcer has been offloaded for 14 days prior to randomization.
8. Index ulcer has not reduced in area > 20% from Day -14 to Day 0, prior torandomization.
9. Subject understands and is willing to participate in the clinical study and can complywith weekly visits and the follow-up regimen.
10. Subject, or their Legally Authorized Representative (LAR), has read, understood, andsigned the IRB/IEC approved Informed Consent Form before screening procedures areundertaken.

Exclusion Criteria:

1. Index ulcer(s) deemed by the investigator to be caused by a medical condition otherthan diabetes.
2. Treatment with HBO wound dressings that include growth factors, bioengineered tissues,or skin substitutes within 30 days of randomization.
3. History of bone cancer or metastatic disease of the affected limb or chemotherapywithin the 12 months prior to randomization.
4. Subjects with a history of more than two weeks treatment with immunosuppressants (including prednisone 10 mg daily or an equivalent does of other oral steroidscytotoxic chemotherapy, or application of topical steroids to the ulcer surface withinone month prior to first Screening Visit, or who receive such medications during thescreening period, or who are anticipated to require such medications during the courseof the study.
5. Subject is on any investigational drug(s) or therapeutic device(s) within 30 dayspreceding the first Screening Visit.
6. History of radiation at the ulcer site.
7. Index ulcer has been previously treated or will need to be treated with any prohibitedtherapies within 30 days prior to randomization.
8. Presence of any condition(s) which seriously compromises the subject's ability tocomplete this study or has a known history of poor adherence with medical treatment.
9. Active infection at the index ulcer at the time of Randomization.
10. Acute osteomyelitis or bone infection of the affected foot, where subject has receivedless than 4 weeks of systemic antibiotics at the time of Screening and less than 6weeks prior to Randomization (systemic antibiotic regimen must be completed at thetime of Randomization).
11. Subject's with suspected infection who have received less than 2 weeks of systemicantibiotics, or have not had surgical resection of clinically diagnosed osteomyelitis
12. Subjects with suspected osteomyelitis who have not had an X-ray, CT scan or MRI within 14 days prior to Randomization.
13. Subject is unwilling or unable to comply with the study requirement for offloading theindex wound
14. Subject is pregnant or breast feeding.